Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel in Ischemic Stroke
NCT05553613Phase 3Completed
- Sponsor
- Kafrelsheikh University
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ticagrelor in ischemic stroke (2 arms), sponsored by Kafrelsheikh University. Primary endpoints: Rate of new ischemic stroke at 90 days and Rate of drug hemorrhagic complications at 90 days. Started Oct 2022; status: completed.
02
Drugs
ticagrelor
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05553613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553613.